Premium
S pectra O ptia granulocyte apheresis collections result in higher collection efficiency of viable, functional neutrophils in a randomized, crossover, multicenter trial
Author(s) -
Cancelas Jose A.,
Padmanabhan Anand,
Le Tuan,
Ambruso Daniel R.,
Rugg Neeta,
Worsham D. Nicole,
Pinkard Susan L.,
Graminske Sharon,
Buck Jennifer,
Goldberg Julie,
Bill Jerry
Publication year - 2015
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/trf.12907
Subject(s) - apheresis , medicine , granulocyte , granulocyte colony stimulating factor , crossover study , plateletpheresis , hematocrit , neutropenia , platelet , surgery , placebo , chemotherapy , pathology , alternative medicine
Background Granulocyte transfusion from healthy donors is used in the treatment of patients with granulocyte function defects, or transient neutropenia and severe bacterial or fungal infections resistant to maximal antimicrobial treatment. Study Design and Methods This study evaluated the performance and safety of the newly developed granulocyte collection protocol of the S pectra O ptia in a prospective, multicenter, open‐label, randomized, paired crossover trial compared with the COBE S pectra apheresis system in a population of 32 evaluable healthy subjects. All subjects received granulocyte–colony‐stimulating factor and dexamethasone before collection. Results Granulocyte procedures from S pectra O ptia apheresis procedures had an approximately 23% higher polymorphonuclear ( PMN ) collection efficiency ( CE ) than the COBE S pectra collections (mean, 53.7% vs. 43.2%; p < 0.01), while the platelet CE (10.9% vs. 10.8%, respectively) and hematocrit (7.4% vs. 7.4%) were comparable between collections on both devices. S pectra O ptia collections generated a higher total PMN yield per liter of blood processed than those produced by the COBE S pectra (with means of 8.6 × 10 10 vs. 6.8 × 10 10 , respectively). Granulocyte viability was more than 99% with both devices, and chemotaxic and bacterial killing activities of circulating versus collected granulocytes were similarly preserved. Fewer operator adjustments were required with S pectra O ptia and there was no significant difference in the number or intensity of adverse events between instruments. Conclusion CE of the granulocyte collection procedure with the S pectra O ptia was approximately 10 percentage points higher than with the COBE S pectra, required less operator involvement, and is safe for clinical implementation.